Remarkably, several of these target genes were down-regulated following miR-Combo treatment (Fig. 3B, C), and have been shown to be involved in GBM progression (RAP2A) [23], angiogenesis (SPON2) [24], migration (CXCR4) [25], and are associated with an increase in tumor grade (IGF2BP3, SERPINH1) [26, 27]. The gene discussed is IGF2BP3; the disease is glioblastoma.